Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Imaging
    • Nanotechnology
    • Semiconductors
  • Controlled Environments
    • Cleanrooms
    • Graphene
    • Lasers
    • Regulations/Standards
    • Sensors
  • Scientific Computing
    • Big Data
    • HPC/Supercomputing
    • Informatics
    • Security
    • Software
  • R&D 100 Awards
    • ENTER NOW
    • 2020 Winners
    • Winner Archive
    • R&D 100 Conference
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • 2021 Funding Forecast
  • COVID-19

The Resilience Planning and Analysis Tool (RAPT)

Established in 1963, the R&D 100 Awards is the only S&T (science and technology) awards competition that recognizes new commercial products, technologies and materials for their technological significance that are available for sale or license. The R&D 100 Awards have long been a benchmark of excellence for industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology. This year's R&D 100 2020 winner is listed below in their respective category.
 
Category: Software/Services
Developers: Argonne National Laboratory
Co-Developers: Federal Emergency Management Agency
United States

Product Description:Impacts from large disasters can spread across cities and regions through interconnected infrastructure systems, affecting vulnerable populations more acutely. While many jurisdictions have their own resilience-related analysis tools, the underlying methodologies may not be accessible. This prompted the Argonne National Laboratory team to develop a tool incorporating the resilience indicators validated by scientific consensus. The Resilience Planning and Analysis Tool (RAPT) enables emergency managers to see relationships among indicators, examine risk vs. resilience and communicate more effectively with at-risk populations. Having these data layers housed within one tool helps EMs to better address resilience barriers. Since spring, FEMA has trained nearly 3,500 people via webinars on its use, most recently at the start of hurricane season. The USACE used RAPT in its strategic contingency contracting process in determining likely locations for alternate care facilities (e.g., pop-up hospitals) during COVID; and the NWS’s chief meteorologist has noted that RAPT identifies new issues and underlying problems that would hinder resilience. RAPT use is clearly resonating within the resilience community.

R&D 100 entry_RAPT_opening screen.JPG

Back to full list of 2020 R&D Winners
Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Imaging
    • Nanotechnology
    • Semiconductors
  • Controlled Environments
    • Cleanrooms
    • Graphene
    • Lasers
    • Regulations/Standards
    • Sensors
  • Scientific Computing
    • Big Data
    • HPC/Supercomputing
    • Informatics
    • Security
    • Software
  • R&D 100 Awards
    • ENTER NOW
    • 2020 Winners
    • Winner Archive
    • R&D 100 Conference
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • 2021 Funding Forecast
  • COVID-19